Literature DB >> 15599469

Clinical characteristics of childhood erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in Taiwanese children.

Nga-Shuen Lam1, Yao-Hsu Yang, Li-Chieh Wang, Yu-Tsan Lin, Bor-Luen Chiang.   

Abstract

Erythema multiforme (EM), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are mucocutaneous diseases associated with significant morbidity and mortality. This study compared childhood EM, SJS and TEN in terms of clinical courses, laboratory data, etiologies and outcomes in Taiwan. The initial laboratory findings, clinical presentations, etiologies and subsequent clinical courses of 30 patients with a diagnosis of EM, SJS or TEN, who were admitted between 1995 and 2003 at National Taiwan University Hospital were included and analyzed. There were 19 cases of EM, 8 cases of SJS, 2 cases of SJS/TEN and 1 case of TEN. The most common etiology in EM was infection (84.2%), and the most common implicated organism was Mycoplasma pneumoniae (42.1%). In contrast, 75% of SJS and 100% of TEN were induced by drugs. The most common offending drug was carbamazepine. Those patients with underlying diseases had more protracted courses and longer hospitalization stays. No mortalities were found in our cases. Early short-term steroid equivalent to 1-2 mg/kg/day of prednisolone for 3-5 days was used in 87.5% of SJS patients, without any significant side effects. Those with poor responsiveness to steroids and protracted courses were treated with additional intravenous immunoglobulin (IVIG) [1 g/kg/day], with satisfactory results. Early ophthalmic consultations were performed in all cases. No ocular complications were found in our cases. In conclusion, EM, SJS and TEN were associated with significant morbidity. Early ophthalmic consultations and withdrawal of the offending medication was necessary. Early short-term use of steroids in SJS showed promising results without significant side effects. The additional IVIG in those who had a poor response to steroid treatment may be helpful.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15599469

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  8 in total

1.  Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States.

Authors:  Derek Y Hsu; Joaquin Brieva; Nanette B Silverberg; Amy S Paller; Jonathan I Silverberg
Journal:  J Am Acad Dermatol       Date:  2017-03-09       Impact factor: 11.527

2.  New insights in toxic epidermal necrolysis (Lyell's syndrome): clinical considerations, pathobiology and targeted treatments revisited.

Authors:  Philippe Paquet; Gérald E Piérard
Journal:  Drug Saf       Date:  2010-03-01       Impact factor: 5.606

3.  Genetic predisposition to oxcarbazepine induced Stevens-Johnson syndrome.

Authors:  Pranay Wal; Ankita Wal; Umeshwar Pandey; Awani K Rai; Anil Bhandari
Journal:  Indian J Crit Care Med       Date:  2011-07

4.  Retrospective analysis of stevens-johnson syndrome and toxic epidermal necrolysis over a period of 10 years.

Authors:  Abarna Devi Sanmarkan; Tukaram Sori; Devinder Mohan Thappa; T J Jaisankar
Journal:  Indian J Dermatol       Date:  2011-01       Impact factor: 1.494

5.  Causative Drugs and Clinical Outcome in Stevens Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and SJS-TEN Overlap in Children.

Authors:  Gomathy Sethuraman; Vinod K Sharma; Pooja Pahwa; Pooja Khetan
Journal:  Indian J Dermatol       Date:  2012-05       Impact factor: 1.494

6.  Vesicobullous disorders of female genitalia.

Authors:  Taru Garg; Saurabh Mittal
Journal:  Indian J Sex Transm Dis AIDS       Date:  2012-01

7.  Stevens-Johnson syndrome/erythema multiforme major and Chlamydia pneumoniae infection in young patients.

Authors:  Ana Filipa Duarte; Maria João Cruz; Elisabete Moreira; Teresa Baudrier; Alberto Mota; Filomena Azevedo
Journal:  Dermatol Reports       Date:  2010-03-31

8.  Oxcarbazepine-induced Stevens Johnson syndrome: A rare case report.

Authors:  S R Sharma; Nalini Sharma; M E Yeolekar
Journal:  Indian Dermatol Online J       Date:  2011-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.